Magstim, the pioneer of a revolutionary non-invasive treatment for depression has announced that its latest TMS therapy product; the Horizon Performance, has achieved CE mark regulatory approval and 510(k) clearance from the FDA.
Magstim is the brains behind Transcranial Magnetic Stimulation (TMS), an innovative and proven therapy which uses a series of repetitive, brief and highly focussed magnetic pulses to stimulate brain cells.
The CE marked Horizon Performance is its first all-in-one TMS therapy solution for practitioners, allowing greater flexibility for patient treatment without systemic or adverse cognitive effects*.
The new, user-friendly The Horizon Performance system provides the opportunity to treat more patients by offering increased cooling capabilities, efficiency and versatility. It reduces treatment time from 37 minutes to 19 minutes with less wait times between sessions.
Magstim has designed Horizon Performance with a proprietary energy recovery system that ensures consistent dosage throughout a treatment session. This is a feature that distinguishes Magstim among other TMS developers.
Additionally, the Horizon Ez-Arm provides secure and effortless coil positioning that provides a best in class comprehensive TMS System.
In depressed patients, electrical activity in certain areas of the brain is reduced. The Horizon TMS therapy uses a focused electromagnetic coil to rapidly pulse a magnetic field to the targeted area of the brain. The small electrical current stimulates the targeted brain cells into activity, increasing brain activity back to a normal level.
TMS is increasingly being adopted by psychiatrists in cases where antidepressant medication is ineffective and before invasive treatments like Electroconvulsive Therapy (ECT) are considered.
The Horizon Performance system allows clinicians to treat more patients by offering a more versatile and efficient solution. It reduces treatment time from 37 minutes to 19 minutes with less wait times between sessions. It is also optimized for patient comfort and ease of use for technicians due to its weightless coil positioning.
Magstim’s Group CEO Lothar Krinke said: “Our launch of Horizon Performance reflects our continued momentum and commitment to innovation. We are confident that this best in class system will benefit a broader range of patients and simplify the treatment for clinicians and their staff”.
Dr Andrew Leuchter, Professor of Psychiatry and Director of the Neuromodulation Division at the Semel Institute of Neuroscience and Human Behavior at UCLA, said: “It is exciting to see continued product development and innovation in TMS technology. Magstim’s Horizon Performance system has a number of features that have great potential to benefit patients. The flexibility of this new device to deliver stimulation at a wide range of frequencies and intensities make it a very attractive system for clinicians as well as researchers.”
Magstim, the pioneer in TMS, developed the first TMS technology over 30 years ago, and has continued to be a leader in the field. Magstim has two primary locations – in Whitland, West Wales and Minnesota, USA.
Media enquiries to Jo Wallace or Alex Harris at Yogi on 02920
or firstname.lastname@example.org or email@example.com
* Carpenter, L et al. Transcranial Magnetic Stimulation (TMS) for Major Depression: A multi-site, naturalistic, observational study of acute treatment outcomes in clinical practice (2012)” Depress Anxiety 2012: 29, 587-596.
The first two sessions of our Magstim Academy lecture series have been a resounding success with several hundred registrants joining us from across the globe. We are now looking forward
Magstim Academy Lecture Series – Rhythm and Acceleration – recent advances in TMS treatment for mood disorders. Mark George, MD, Nolan Williams, MD and Martijn Arns, PhD will present on their recently published and on-going TMS studies.